HS
Therapeutic Areas
Swedish Orphan Biovitrum Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BIVV001 (rFVIIIFc-VWF-XTEN) | Hemophilia A | Phase 3 |
| Doptelet (avatrombopag) | Chronic Immune Thrombocytopenia (ITP) | Marketed / Phase 4 |
| Gamifant (emapalumab) | Primary Hemophagocytic Lymphohistiocytosis (HLH) | Marketed / Phase 2/3 |
| Kineret (anakinra) | Autoinflammatory Diseases (e.g., CAPS, FMF) | Marketed |
| SEL-212 | Refractory Gout | Phase 3 |
Leadership Team at Swedish Orphan Biovitrum
GO
Guido Oelkers
Chief Executive Officer and President
JR
Johan Råstam
EVP, R&D and Chief Medical Officer
RL
Rami Levin
EVP, Chief Commercial Officer
KF
Karin Fischer
EVP, People & Culture
AU
Anders Ullman
EVP, Medical & Scientific Affairs